Botulinum Toxin Type A - Administration & dosage
Research News and Information

Sunday, November 22, 2009

Robot-mediated and clinical scales evaluation after upper limb botulinum toxin type A injection in children with hemiplegia.

30 Oct 2009 OBJECTIVE: The aim of this pilot study was to examine changes in different aspects of impairment, including spasticity in the upper limbs, of hemiplegic children following botulinum toxin type A intervention. Progress was assessed using standard ... Read more...

The combined use of forced cold air and topical anesthetic cream for analgesia during the treatment of palmar hyperhydrosis with botulinum toxin injections.

29 Sep 2009 BACKGROUND: Palmar hyperhidrosis is an uncomfortable condition that can severely affect a patient's quality of life. Injections of botulinum toxin have proven to be an efficient treatment modality, however the pain associated with palmar injections ... Read more...

A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes.

29 Sep 2009 BACKGROUND: Few studies evaluate patient-reported outcomes (PROs). OBJECTIVES: To assess the PROs of treatment with botulinum neurotoxin type A (BoNTA) in upper facial lines; to evaluate two new PRO instruments. METHODS: Prospective, randomized, ... Read more...

Latest indexed articles for 'Botulinum Toxin Type A - Administration & dosage'

These are the very latest articles for this heading:

• Robot-mediated and clinical scales evaluation after upper limb botulinum toxin type A injection in children with hemiplegia. 30 Oct 2009
• The combined use of forced cold air and topical anesthetic cream for analgesia during the treatment of palmar hyperhydrosis with botulinum toxin injections. 29 Sep 2009
• A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes. 29 Sep 2009
• Influence of age and gender on dose and effectiveness of botulinum toxin for laryngeal dystonia. 29 Sep 2009
• Transport molecules using reverse sequence HIV-Tat polypeptides: not just any old Tat? (WO200808225). 30 Aug 2009
• Effects of different dilutions of botulinum toxin type A treatment for children with cerebral palsy with spastic ankle plantarflexor: a randomized controlled trial. 30 Aug 2009
• Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment. 13 Aug 2009
• The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice? 11 Aug 2009
• Is active sweating during heat acclimation required for improvements in peripheral sweat gland function? 3 Aug 2009
• [Local botulinum neurotoxin A therapy in tardive lingual dyskinesia] 30 Jul 2009
• Treatment of superior limbic keratoconjunctivitis with a large-diameter contact lens and Botulium Toxin A. 30 Jul 2009
• [Treatment of lingual dystonia with botulinum toxin injections. First report] 30 Jul 2009
• Novel treatment of first bite syndrome using botulinum toxin type A. 30 Jul 2009
• A placebo-controlled surgical trial of the treatment of migraine headaches. 30 Jul 2009
• Botulinum a toxin/dimethyl sulfoxide bladder instillations for women with refractory idiopathic detrusor overactivity: a phase 1/2 study. 30 Jul 2009
• Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. 18 Jul 2009
• [Botulinum toxin therapy for focal dystonia] 17 Jul 2009
• Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study. Jul 2009
• [Comparison of non-invasive and invasive techniques in the treatment of patients with myofascial pain syndrome.] 29 Jun 2009
• Palmar hyperhidrosis: long-term follow-up of nine children and adolescents treated with botulinum toxin type A. 29 Jun 2009

See a longer list of these articles.

Technical information about 'Botulinum Toxin Type A'

Definition: A 150 kDa neurotoxic protein produced by CLOSTRIDIUM BOTULINUM. When consumed in contaminated food it can cause paralysis and death. In its purified form, it has been used in the treatment of BLEPHAROSPASM and STRABISMUS.

Registry Number: 0

Descriptor UI: D019274

Alternative terms: Botulinum Toxin Type A; Botulinum Neurotoxin A; Neurotoxin A, Botulinum; Clostridium Botulinum Toxin Type A; Botulinum A Toxin; Toxin, Botulinum A; Clostridium botulinum A Toxin; Dysport; Lasa Brand of Botulinum A Toxin; Speywood Brand of Botulinum A Toxin; Ispen Brand of Botulinum A Toxin; Oculinum; Botox; Merz Brand of Botulinum A Toxin; Allergan Brand of Botulinum A Toxin;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Neuromuscular Agents; Neurotoxins;

Tree Number: D12.776.097.156.050; D23.946.123.179.050;

History Note: 97

Technical Notes: /antag permitted but consider also BOTULINUM ANTITOXIN